Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial

Context. Approximately 1 in 20 patients undergoing the percutaneous cardiac intervention (PCI) experience severe procedure-related access-site (A-S) pain. The multimodal pain management model (MPM) can reduce the intensity and prevalence of pain and this approach was not investigated in the postproc...

Full description

Saved in:
Bibliographic Details
Main Authors: Liuda Brogiene, Aiste Urbonaite, Giedre Baksyte, Andrius Macas
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2022/6102793
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568469518811136
author Liuda Brogiene
Aiste Urbonaite
Giedre Baksyte
Andrius Macas
author_facet Liuda Brogiene
Aiste Urbonaite
Giedre Baksyte
Andrius Macas
author_sort Liuda Brogiene
collection DOAJ
description Context. Approximately 1 in 20 patients undergoing the percutaneous cardiac intervention (PCI) experience severe procedure-related access-site (A-S) pain. The multimodal pain management model (MPM) can reduce the intensity and prevalence of pain and this approach was not investigated in the postprocedural pain management area. To address this, a randomized controlled trial was conducted in Hospital of Lithuanian University of Health Sciences Kauno klinikos in 2018. Methods. 137 patients who underwent PCI procedure via radial artery were randomly assigned (1 : 1) to the control (CG, n = 68) and intervention (IG, n = 65) groups. IG received MPM (paracetamol, ibuprofen, and the arm physiotherapy), CG received pain medication “as needed.” Outcomes were assessed immediately after, 2, 12, 24, and 48 h, 1 week, and 1 and 3 months after PCI. The primary outcome was A-S pain prevalence and pain intensity numeric rating scale (NRS) 0–10. Results. Results showed that A-S pain prevalence during the 3-month follow-up period was decreasing. Statistically significant difference between the groups (CG versus IG) was after 24 h (41.2% versus 18.5, p=0.005), 48 h (30.9% versus 1.5%, p≤0.001), 1 week (25% versus 10.8%, p=0.042), 1 month (23.5% versus 7.7%, p=0.017) after the procedure. The mean of the highest pain intensity was after 2 h (IG-2.17 ± 2.07; CG-3.53 ± 2.69) and the lowest 3 months (IG-0.02 ± 0.12; CG-0.09 ± 0.45) after the procedure. A-S pain intensity mean scores were statistically significantly higher in CG during the follow-up period (Wilks’ λ = 0.84 F (7,125) = 3.37, p=0.002). Conclusion. In conclusion, MPM approach can reduce A-S pain prevalence and pain intensity after PCI. More randomized control studies are needed.
format Article
id doaj-art-f73b82b6a74f4c01b7c9e4799e5394e3
institution Kabale University
issn 1918-1523
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-f73b82b6a74f4c01b7c9e4799e5394e32025-02-03T00:59:08ZengWileyPain Research and Management1918-15232022-01-01202210.1155/2022/6102793Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control TrialLiuda Brogiene0Aiste Urbonaite1Giedre Baksyte2Andrius Macas3Anesthesiology DepartmentAnesthesiology DepartmentCardiology DepartmentAnesthesiology DepartmentContext. Approximately 1 in 20 patients undergoing the percutaneous cardiac intervention (PCI) experience severe procedure-related access-site (A-S) pain. The multimodal pain management model (MPM) can reduce the intensity and prevalence of pain and this approach was not investigated in the postprocedural pain management area. To address this, a randomized controlled trial was conducted in Hospital of Lithuanian University of Health Sciences Kauno klinikos in 2018. Methods. 137 patients who underwent PCI procedure via radial artery were randomly assigned (1 : 1) to the control (CG, n = 68) and intervention (IG, n = 65) groups. IG received MPM (paracetamol, ibuprofen, and the arm physiotherapy), CG received pain medication “as needed.” Outcomes were assessed immediately after, 2, 12, 24, and 48 h, 1 week, and 1 and 3 months after PCI. The primary outcome was A-S pain prevalence and pain intensity numeric rating scale (NRS) 0–10. Results. Results showed that A-S pain prevalence during the 3-month follow-up period was decreasing. Statistically significant difference between the groups (CG versus IG) was after 24 h (41.2% versus 18.5, p=0.005), 48 h (30.9% versus 1.5%, p≤0.001), 1 week (25% versus 10.8%, p=0.042), 1 month (23.5% versus 7.7%, p=0.017) after the procedure. The mean of the highest pain intensity was after 2 h (IG-2.17 ± 2.07; CG-3.53 ± 2.69) and the lowest 3 months (IG-0.02 ± 0.12; CG-0.09 ± 0.45) after the procedure. A-S pain intensity mean scores were statistically significantly higher in CG during the follow-up period (Wilks’ λ = 0.84 F (7,125) = 3.37, p=0.002). Conclusion. In conclusion, MPM approach can reduce A-S pain prevalence and pain intensity after PCI. More randomized control studies are needed.http://dx.doi.org/10.1155/2022/6102793
spellingShingle Liuda Brogiene
Aiste Urbonaite
Giedre Baksyte
Andrius Macas
Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
Pain Research and Management
title Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
title_full Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
title_fullStr Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
title_full_unstemmed Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
title_short Procedure-Related Access Site Pain Multimodal Management following Percutaneous Cardiac Intervention: A Randomized Control Trial
title_sort procedure related access site pain multimodal management following percutaneous cardiac intervention a randomized control trial
url http://dx.doi.org/10.1155/2022/6102793
work_keys_str_mv AT liudabrogiene procedurerelatedaccesssitepainmultimodalmanagementfollowingpercutaneouscardiacinterventionarandomizedcontroltrial
AT aisteurbonaite procedurerelatedaccesssitepainmultimodalmanagementfollowingpercutaneouscardiacinterventionarandomizedcontroltrial
AT giedrebaksyte procedurerelatedaccesssitepainmultimodalmanagementfollowingpercutaneouscardiacinterventionarandomizedcontroltrial
AT andriusmacas procedurerelatedaccesssitepainmultimodalmanagementfollowingpercutaneouscardiacinterventionarandomizedcontroltrial